| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Toxicity/Toxicokinetics |
Toxicity Summary
Methoxytyrosine is one of the main biochemical markers of aromatic L-amino acid decarboxylase deficiency, a congenital metabolic defect that affects the biosynthesis of serotonin and dopamine. Elevated levels of 3-methoxytyrosine are found in cerebrospinal fluid, plasma, and urine. Catechol-O-methyltransferase, the enzyme responsible for the production of 3-methoxytyrosine, is derived from levodopa in many organs. However, its half-life (approximately 15 hours) is longer than that of levodopa (approximately 1 hour). This means it accumulates in the plasma and brain tissue of patients receiving long-term levodopa treatment (e.g., those with Parkinson's disease). 3-Methoxytyrosine has some influence on levodopa-related motor dysfunction, including inhibiting striatal tyrosine uptake, competing with levodopa for transport along the blood-brain barrier, and inhibiting dopamine release. 3-Methoxytyrosine also increases homocysteine levels, an amino acid that can induce cardiovascular disease and neuronal damage. Other toxic effects may include oxidative DNA damage (which can lead to cell death), decreased motility, and reduced mitochondrial membrane potential. (Wikipedia) |
|---|---|
| References | |
| Additional Infomation |
3-O-methyldopa is a derivative of L-tyrosine, specifically a 3-methoxy derivative of L-DOPA. It plays a metabolic role in the human body. It is an L-tyrosine derivative, a monomethoxybenzene, and a non-protein-derived L-α-amino acid. Functionally, it is related to L-DOPA. It is a zwitterion tautomer of 3-O-methyldopa.
|
| Molecular Formula |
C10H13NO4
|
|---|---|
| Molecular Weight |
211.21
|
| Exact Mass |
211.084
|
| CAS # |
300-48-1
|
| Related CAS # |
3-O-Methyl-DL-DOPA;7636-26-2;3-O-Methyldopa-d3;586954-09-8;3-O-Methyldopa-d3 hydrate
|
| PubChem CID |
9307
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
1.321g/cm3
|
| Boiling Point |
407.3ºC at 760mmHg
|
| Flash Point |
200.1ºC
|
| Index of Refraction |
1.591
|
| LogP |
1.055
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
15
|
| Complexity |
222
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
COC1=C(C=CC(=C1)C[C@@H](C(=O)O)N)O
|
| InChi Key |
PFDUUKDQEHURQC-ZETCQYMHSA-N
|
| InChi Code |
InChI=1S/C10H13NO4/c1-15-9-5-6(2-3-8(9)12)4-7(11)10(13)14/h2-3,5,7,12H,4,11H2,1H3,(H,13,14)/t7-/m0/s1
|
| Chemical Name |
(2S)-2-amino-3-(4-hydroxy-3-methoxyphenyl)propanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: 16.67 mg/mL (78.93 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 10 mg/mL (47.35 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.7346 mL | 23.6731 mL | 47.3462 mL | |
| 5 mM | 0.9469 mL | 4.7346 mL | 9.4692 mL | |
| 10 mM | 0.4735 mL | 2.3673 mL | 4.7346 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
